title: [Effect of cycloferon on dissemination of Lewis lung carcinoma in mice and rhabdomyosarcoma ra-23 in rats].
abstract: Tumor growth and proliferative activity of tumor cells were suppressed and the number of pulmonary metastases in C57B16 mice decreased 3.3-fold following seven injections of cycloferon (100 mg/kg body) to induce interferon production. Injections were carried out 1-16 days after subcutaneous transplantation of Lewis lung carcinoma. After mice were immunized with ovine red blood cells, cycloferon administration raised thymus-dependent humoral immune response. After eight injections of cycloferon (50 mg/kg body) into rats, from day of intravenous transplantation of rhabdomyosarcoma RA-23 until day 20, no significant effect on metastasizing into the lung was recorded. However, single injection of cyclophosphamide 50 mg/kg inhibited metastasis formation. The highest suppressor effect was registered with combination cycloferon-cyclophophamide treatment: mean weight of metastasis decreased by half, as compared with treatment with cyclophosphamide alone. Both drugs caused karyotypical abnormalities to occur in metastatic cells. Tumor growth and spreading suppression after cycloferon should be attributed to cytotoxic antitumor action, cell proliferation inhibition and immunomodulating effect.
authors.affiliation: N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
authors.forename: M A
authors.initials: MA
authors.lastname: Zabezhinskii
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
authors.forename: I M
authors.initials: IM
authors.lastname: Kvetnoi
authors.forename: V V
authors.initials: VV
authors.lastname: Iuzhakov
authors.forename: V V
authors.initials: VV
authors.lastname: Popuchiev
authors.forename: Iu B
authors.initials: IuB
authors.lastname: Bakhtin
authors.forename: E V
authors.initials: EV
authors.lastname: Kaminskaia
authors.forename: S N
authors.initials: SN
authors.lastname: Proshin
authors.forename: I G
authors.initials: IG
authors.lastname: Popovich
authors.forename: E A
authors.initials: EA
authors.lastname: Zaripova
authors.forename: V N
authors.initials: VN
authors.lastname: Anisimov
mesh_terms: D000166:Acridines / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control* / Q000556:secondary; D002455:Cell Division / Q000187:drug effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D007267:Injections; D007369:Interferon Inducers / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control* / Q000556:secondary
chemical_list: D000166:Acridines; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D007369:Interferon Inducers; D003520:Cyclophosphamide; C026430:10-carboxymethyl-9-acridanone